Peter C. Hollenhorst
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Peter C. Hollenhorst has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
- Nur Pradani Damayanti
Genitourinary Program, Division of Hematology & Oncology, Indiana University, Indianapolis, Indiana
120 shared publications - Angela J. Klunk
Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana
116 shared publications - Christopher Rupert
Division of Hematology and Oncology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York
116 shared publications - David E. Heppner
University at Buffalo
116 shared publications - Ilaria Delle Fontane
Division of Hematology and Oncology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York
116 shared publications - Kirk A. Staschke
Department of Biochemistry and Molecular Biology, Indiana University School of Medicine
116 shared publications
Latest Publications
- Open Access
Oncogenic ETS factors expressed from fusion genes utilize EWSR1 to associate with the paraspeckle and regulate transcription
ETS family transcription factors are aberrantly expressed in prostate cancer and Ewing sarcoma due to chromosomal rearrangements resulting in fusion genes, most commonly TMPRSS2::ERG and EWSR1::FLI1 , respectively. The products of these gene fusions regulate transcription together with the intrinsically disordered protein EWSR1. However, the role of EWSR1 as a transcriptional co-regulator is not fully understood. EWSR1 can undergo liquid-liquid phase separation. We found that ERG could integrate into EWSR1 phase separated droplets. We then tested the role of the paraspeckle, a nuclear membraneless organelle known to regulate transcription and include EWSR1. Both ERG and EWSR1::FLI1 associated with the paraspeckle scaffold long non-coding RNA NEAT1_2. Disruption of paraspeckles in prostate cancer and Ewing sarcoma cell lines resulted in disruption of oncogenic phenotypes mimicking the loss of oncogenic ETS factors. In Ewing sarcoma cells paraspeckle disruption promoted similar transcriptional profiles as loss of EWSR1::FLI1. Further, loss of EWSR1::FLI1 reduced the association of a paraspeckle component with EWSR1::FLI1 target genomic loci. In TMPRSS2::ERG positive prostate cancer cells paraspeckle disruption correlated with ERG-mediated transcriptional repression. These findings suggest that the paraspeckle is an important transcriptional regulator in cancers with ETS gene fusions and provides a potential target for further mechanistic understanding and drug development.
Open AccessOncogenic ETS factors expressed from fusion genes utilize EWSR1 to associate with the paraspeckle and regulate transcription
ETS family transcription factors are aberrantly expressed in prostate cancer and Ewing sarcoma due to chromosomal rearrangements resulting in fusion genes, most commonly TMPRSS2::ERG and EWSR1::FLI1 , respectively. The products of these gene fusions regulate transcription together with the intrinsically disordered protein EWSR1. However, the role of EWSR1 as a transcriptional co-regulator is not fully understood. EWSR1 can undergo liquid-liquid phase separation. We found that ERG could integrate into EWSR1 phase separated droplets. We then tested the role of the paraspeckle, a nuclear membraneless organelle known to regulate transcription and include EWSR1. Both ERG and EWSR1::FLI1 associated with the paraspeckle scaffold long non-coding RNA NEAT1_2. Disruption of paraspeckles in prostate cancer and Ewing sarcoma cell lines resulted in disruption of oncogenic phenotypes mimicking the loss of oncogenic ETS factors. In Ewing sarcoma cells paraspeckle disruption promoted similar transcriptional profiles as loss of EWSR1::FLI1. Further, loss of EWSR1::FLI1 reduced the association of a paraspeckle component with EWSR1::FLI1 target genomic loci. In TMPRSS2::ERG positive prostate cancer cells paraspeckle disruption correlated with ERG-mediated transcriptional repression. These findings suggest that the paraspeckle is an important transcriptional regulator in cancers with ETS gene fusions and provides a potential target for further mechanistic understanding and drug development.
- Open Access
- 15 June 2026
- Published by Springer Nature in Research Square
ERG function in prostate cells is regulated by distinct positive feedback loops depending on AKT signaling status
A chromosomal rearrangement that causes aberrant expression of the ERG transcription factor is the most common genomic alteration in prostate cancer. Expression of ERG in prostate cells can promote either luminal epithelial or mesenchymal cell fates depending on the status of the PI3K/AKT signaling pathway. Phosphorylation of ERG by ERK is important for oncogenic activity and can be regulated by the TLR4 signaling pathway. Here we found that the PI3K/AKT pathway not only regulated how ERG promoted distinct cell types within prostate cells, but also altered the positive-feedback loops that drove ERG phosphorylation. Activation of AKT signaling switched the upstream pathway that promotes ERG phosphorylation from TLR4 to VEGF. Inhibition of the PI3K/AKT pathway in ERG-positive prostate cells resulted in loss of androgen receptor expression, gain of mesenchymal markers and loss of sensitivity to androgen receptor inhibition. Further, androgen depletion reduced PI3K/AKT activity while increasing MEK/ERK activity and relative ERG phosphorylation. In a xenograft model, single agent inhibition of TLR4 or VEGFA reduced ERG phosphorylation, tumor size, and luminal marker expression but increased mesenchymal marker expression. Combination TLR4/VEGFA inhibition reduced tumor size and reduced both luminal and mesenchymal markers. These findings suggest novel combinatorial treatments for ERG-positive prostate cancer.
- 15 June 2026
- Published by Springer Nature in Research Square
Open AccessERG function in prostate cells is regulated by distinct positive feedback loops depending on AKT signaling status
A chromosomal rearrangement that causes aberrant expression of the ERG transcription factor is the most common genomic alteration in prostate cancer. Expression of ERG in prostate cells can promote either luminal epithelial or mesenchymal cell fates depending on the status of the PI3K/AKT signaling pathway. Phosphorylation of ERG by ERK is important for oncogenic activity and can be regulated by the TLR4 signaling pathway. Here we found that the PI3K/AKT pathway not only regulated how ERG promoted distinct cell types within prostate cells, but also altered the positive-feedback loops that drove ERG phosphorylation. Activation of AKT signaling switched the upstream pathway that promotes ERG phosphorylation from TLR4 to VEGF. Inhibition of the PI3K/AKT pathway in ERG-positive prostate cells resulted in loss of androgen receptor expression, gain of mesenchymal markers and loss of sensitivity to androgen receptor inhibition. Further, androgen depletion reduced PI3K/AKT activity while increasing MEK/ERK activity and relative ERG phosphorylation. In a xenograft model, single agent inhibition of TLR4 or VEGFA reduced ERG phosphorylation, tumor size, and luminal marker expression but increased mesenchymal marker expression. Combination TLR4/VEGFA inhibition reduced tumor size and reduced both luminal and mesenchymal markers. These findings suggest novel combinatorial treatments for ERG-positive prostate cancer.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from PRC2/FOXO1-Mediated Repression Determines Interchangeability of ETS Oncogenes in Prostate Cancer and Ewing Sarcoma
Figure S1. ETV1, ETV4, and ETV5, but not ERG can rescue colony formation upon EWSR1::FLI1 knockdown in A673 Ewing sarcoma cells.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from PRC2/FOXO1-Mediated Repression Determines Interchangeability of ETS Oncogenes in Prostate Cancer and Ewing Sarcoma
Figure S1. ETV1, ETV4, and ETV5, but not ERG can rescue colony formation upon EWSR1::FLI1 knockdown in A673 Ewing sarcoma cells.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Data from PRC2/FOXO1-Mediated Repression Determines Interchangeability of ETS Oncogenes in Prostate Cancer and Ewing Sarcoma
Genes encoding ETS family transcription factors are altered by chromosomal rearrangement in 60% to 70% of prostate cancers and nearly all Ewing sarcomas. Ewing sarcoma rearrangements result in chimeric fusion of ETS proteins to the RNA-binding protein EWSR1. Prostate cancer rearrangements result in aberrant expression of ETS proteins such as ETV1, ETV4, ETV5, or ERG that can interact with wild-type EWSR1, suggesting common mechanisms between these diseases. In this study, we find that ETV1, ETV4, and ETV5 can phenocopy EWSR1::FLI1 in Ewing sarcoma cell lines. However, rescue of EWSR1::FLI1 knockdown by ERG requires an ERG mutant that disrupts interaction with polycomb repressive complex 2 (PRC2). This suggests that EWSR1::ERG fusions that drive Ewing sarcoma avoid PRC2 interactions. We then identify an endogenous PRC2/FOXO1 complex and demonstrate that FOXO1 bridges ERG/PRC2 interaction. AKT-mediated degradation of FOXO1 and subsequent loss of the ERG/PRC2 interaction provide a mechanism for ERG synergy with PTEN deletion in prostate cancer.Implications:These findings indicate that ETS transcription factors that drive prostate cancer and Ewing sarcoma utilize similar mechanisms and thus could be targeted by similar therapeutic approaches.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from PRC2/FOXO1-Mediated Repression Determines Interchangeability of ETS Oncogenes in Prostate Cancer and Ewing Sarcoma
Genes encoding ETS family transcription factors are altered by chromosomal rearrangement in 60% to 70% of prostate cancers and nearly all Ewing sarcomas. Ewing sarcoma rearrangements result in chimeric fusion of ETS proteins to the RNA-binding protein EWSR1. Prostate cancer rearrangements result in aberrant expression of ETS proteins such as ETV1, ETV4, ETV5, or ERG that can interact with wild-type EWSR1, suggesting common mechanisms between these diseases. In this study, we find that ETV1, ETV4, and ETV5 can phenocopy EWSR1::FLI1 in Ewing sarcoma cell lines. However, rescue of EWSR1::FLI1 knockdown by ERG requires an ERG mutant that disrupts interaction with polycomb repressive complex 2 (PRC2). This suggests that EWSR1::ERG fusions that drive Ewing sarcoma avoid PRC2 interactions. We then identify an endogenous PRC2/FOXO1 complex and demonstrate that FOXO1 bridges ERG/PRC2 interaction. AKT-mediated degradation of FOXO1 and subsequent loss of the ERG/PRC2 interaction provide a mechanism for ERG synergy with PTEN deletion in prostate cancer.Implications:These findings indicate that ETS transcription factors that drive prostate cancer and Ewing sarcoma utilize similar mechanisms and thus could be targeted by similar therapeutic approaches.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from PRC2/FOXO1-Mediated Repression Determines Interchangeability of ETS Oncogenes in Prostate Cancer and Ewing Sarcoma
Figure S2. ERG S96E supports viability and colony formation in TC-71 Ewing sarcoma cell lines and reduces migration in A673.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from PRC2/FOXO1-Mediated Repression Determines Interchangeability of ETS Oncogenes in Prostate Cancer and Ewing Sarcoma
Figure S2. ERG S96E supports viability and colony formation in TC-71 Ewing sarcoma cell lines and reduces migration in A673.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from PRC2/FOXO1-Mediated Repression Determines Interchangeability of ETS Oncogenes in Prostate Cancer and Ewing Sarcoma
Figure S3. EZH2 inhibition enables ERG to restore colony formation in A673. A) A673-Vector and ERG-expressing cells were treated for 96 hours with the indicated GSK503 concentration or DMSO control and H3K27me3 was evaluated via immunoblot.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from PRC2/FOXO1-Mediated Repression Determines Interchangeability of ETS Oncogenes in Prostate Cancer and Ewing Sarcoma
Figure S3. EZH2 inhibition enables ERG to restore colony formation in A673. A) A673-Vector and ERG-expressing cells were treated for 96 hours with the indicated GSK503 concentration or DMSO control and H3K27me3 was evaluated via immunoblot.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from PRC2/FOXO1-Mediated Repression Determines Interchangeability of ETS Oncogenes in Prostate Cancer and Ewing Sarcoma
Table S1. shRNA Primer sequences
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from PRC2/FOXO1-Mediated Repression Determines Interchangeability of ETS Oncogenes in Prostate Cancer and Ewing Sarcoma
Table S1. shRNA Primer sequences
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from PRC2/FOXO1-Mediated Repression Determines Interchangeability of ETS Oncogenes in Prostate Cancer and Ewing Sarcoma
Figure S4. PNT2 cells have low FOXO1 and lack synergy between ERG and AKT.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from PRC2/FOXO1-Mediated Repression Determines Interchangeability of ETS Oncogenes in Prostate Cancer and Ewing Sarcoma
Figure S4. PNT2 cells have low FOXO1 and lack synergy between ERG and AKT.
- Open Access
- 31 December 2025
- Published by Wiley in FEBS Letters
- Vol. 600 (8) , 1248-1262
Multiple ETS family transcription factors bind mutant p53 via distinct interaction regions
ETS family transcription factors can mediate mutant p53 functions, but there has been no comprehensive analysis of p53 interaction across the ETS family. By comparing direct mutant p53 binding between 26 ETS proteins, we found that all bound mutant p53, but relative binding differed significantly. The ETS DNA binding domain provided a common interaction interface, but strong binding required an alternate interaction domain highlighted by a PXXPP motif found in five ETS proteins. Genome‐wide mapping found that the ETS protein ERG mediated some mutant p53 DNA binding in prostate cancer cells. Lastly, ETS proteins that interact strongly with mutant p53 tended to be upregulated in p53 mutant ovarian cancer. These results identify multiple ETS family members that could mediate mutant p53 function in cancer. Impact statement: The mechanisms behind gain‐of‐function mutant p53 remain unclear. Here we identify distinct domains and a novel motif that can mediate binding of mutant p53 to multiple different ETS family transcription factors.
- 31 December 2025
- Published by Wiley in FEBS Letters
- Vol. 600 (8) , 1248-1262
Open AccessMultiple ETS family transcription factors bind mutant p53 via distinct interaction regions
ETS family transcription factors can mediate mutant p53 functions, but there has been no comprehensive analysis of p53 interaction across the ETS family. By comparing direct mutant p53 binding between 26 ETS proteins, we found that all bound mutant p53, but relative binding differed significantly. The ETS DNA binding domain provided a common interaction interface, but strong binding required an alternate interaction domain highlighted by a PXXPP motif found in five ETS proteins. Genome‐wide mapping found that the ETS protein ERG mediated some mutant p53 DNA binding in prostate cancer cells. Lastly, ETS proteins that interact strongly with mutant p53 tended to be upregulated in p53 mutant ovarian cancer. These results identify multiple ETS family members that could mediate mutant p53 function in cancer. Impact statement: The mechanisms behind gain‐of‐function mutant p53 remain unclear. Here we identify distinct domains and a novel motif that can mediate binding of mutant p53 to multiple different ETS family transcription factors.
- 19 September 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 24 (1) , 48-59
PRC2/FOXO1-Mediated Repression Determines Interchangeability of ETS Oncogenes in Prostate Cancer and Ewing Sarcoma
Genes encoding ETS family transcription factors are altered by chromosomal rearrangement in 60% to 70% of prostate cancers and nearly all Ewing sarcomas. Ewing sarcoma rearrangements result in chimeric fusion of ETS proteins to the RNA-binding protein EWSR1. Prostate cancer rearrangements result in aberrant expression of ETS proteins such as ETV1, ETV4, ETV5, or ERG that can interact with wild-type EWSR1, suggesting common mechanisms between these diseases. In this study, we find that ETV1, ETV4, and ETV5 can phenocopy EWSR1::FLI1 in Ewing sarcoma cell lines. However, rescue of EWSR1::FLI1 knockdown by ERG requires an ERG mutant that disrupts interaction with polycomb repressive complex 2 (PRC2). This suggests that EWSR1::ERG fusions that drive Ewing sarcoma avoid PRC2 interactions. We then identify an endogenous PRC2/FOXO1 complex and demonstrate that FOXO1 bridges ERG/PRC2 interaction. AKT-mediated degradation of FOXO1 and subsequent loss of the ERG/PRC2 interaction provide a mechanism for ERG synergy with PTEN deletion in prostate cancer. Implications: These findings indicate that ETS transcription factors that drive prostate cancer and Ewing sarcoma utilize similar mechanisms and thus could be targeted by similar therapeutic approaches.
- 19 September 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 24 (1) , 48-59
PRC2/FOXO1-Mediated Repression Determines Interchangeability of ETS Oncogenes in Prostate Cancer and Ewing Sarcoma
Genes encoding ETS family transcription factors are altered by chromosomal rearrangement in 60% to 70% of prostate cancers and nearly all Ewing sarcomas. Ewing sarcoma rearrangements result in chimeric fusion of ETS proteins to the RNA-binding protein EWSR1. Prostate cancer rearrangements result in aberrant expression of ETS proteins such as ETV1, ETV4, ETV5, or ERG that can interact with wild-type EWSR1, suggesting common mechanisms between these diseases. In this study, we find that ETV1, ETV4, and ETV5 can phenocopy EWSR1::FLI1 in Ewing sarcoma cell lines. However, rescue of EWSR1::FLI1 knockdown by ERG requires an ERG mutant that disrupts interaction with polycomb repressive complex 2 (PRC2). This suggests that EWSR1::ERG fusions that drive Ewing sarcoma avoid PRC2 interactions. We then identify an endogenous PRC2/FOXO1 complex and demonstrate that FOXO1 bridges ERG/PRC2 interaction. AKT-mediated degradation of FOXO1 and subsequent loss of the ERG/PRC2 interaction provide a mechanism for ERG synergy with PTEN deletion in prostate cancer. Implications: These findings indicate that ETS transcription factors that drive prostate cancer and Ewing sarcoma utilize similar mechanisms and thus could be targeted by similar therapeutic approaches.